SMTL ID : 9hrt.1

Structure of human PD-L1 in complex with clinically evaluated inhibitor

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.30 Å

Oligo State

homo-dimer

Ligands

1 x 01: (2~{R})-2-[[3-[(~{E})-2-[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methyl-phenyl]ethenyl]-4-(trifluoromethyl)phenyl]methylamino]-2-methyl-3-oxidanyl-propanoic acid

01.1: 17 residues within 4Å: Chain A: I.40, Y.42, Q.52, M.101, A.107, D.108, Y.109, K.110 Chain B: I.40, Y.42, Q.52, M.101, I.102, S.103, A.107, D.108, Y.109 11 PLIP interactions: 7 interactions with chain A, 4 interactions with chain B Hydrophobic interactions: A:M.101, A:A.107, A:Y.109, A:Y.109, B:Y.42, B:M.101, B:A.107 Hydrogen bonds: A:Q.52, A:Y.109, A:K.110 pi-Stacking: B:Y.42

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Slota, A. et al., Characterization of Clinically Evaluated Small-Molecule Inhibitors of PD-L1 for Immunotherapy. Acs Med.Chem.Lett. (2025)

Release Date

2025-06-18

Peptides

Programmed cell death 1 ligand 1: AB

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

B
B

Programmed cell death 1 ligand 1

Related Entries With Identical Sequence